Retinal Sustained-Drug Delivery Platform

About Glaukos

Glaukos Corporation's mission is to develop and lead the global ophthalmic market with novel therapies that advance the standard of care for chronic eye diseases. The company has achieved a paradigm shift in glaucoma treatment through its market-leading MIGS platform, with over 3 million iStent device implants, and is expanding into corneal and retinal therapeutics. Its strategy leverages a deep commitment to R&D—reinvesting ~30% of sales—to build a robust pipeline of micro-invasive devices and sustained-drug delivery systems, aiming to own the entire treatment continuum in key ophthalmic segments.

Therapeutic Areas